Raymond James downgraded Quipt Home Medical to Market Perform from Outperform with a $10 price target. Quipt reported strong operational performance driving beats on revenue, adjusted EBITDA, and EPS, but disclosed an ongoing civil investigative demand from the US Department of Justice relating to the False Claims Act, the analyst tells investors in a research note. While no determination of wrongdoing has been made, Raymond James expect this to impair sentiment, in the near term or until the market gains greater clarity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QIPT:
- Quipt Home Medical Reports Strong Operating Performance With Record First Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 60% and Adjusted EBITDA Growth of 71%
- QIPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quipt Home Medical Corp. to Announce Fiscal First Quarter 2024 Financial Results on February 14, 2024
- Quipt Home Medical Corp. Announces Filing of Preliminary Base Shelf Prospectus to Replace Recently Expired Base Shelf Prospectus
- Quipt Home Medical files $300M mixed securities shelf
